Pre-treatment C-reactive protein level is a prognostic marker of patients treated with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.

ABSTRACT:

Background

C-reactive protein (CRP) is one of the most important markers reflecting systemic inflammatory response. The objective of this study was to evaluate the prognostic value of CRP in patients undergoing treatment with immune checkpoint inhibitor (ICI) for renal cell carcinoma.

Methods

We performed a systematic search of PubMed, Cochrane Library, and Web of Science databases in July 2024, following the PRISMA statement. A pooled meta-analysis was conducted to assess the prognostic value of CRP. We also evaluated the prognostic values of CRP kinetics.

Results

The search identified 12 non-randomized controlled trials (NRCTs), of which 7 assessed the prognostic value of CRP and 5 evaluated CRP kinetics. Higher CRP level before treatment with ICI was a predictor of

SUBMITTER: Yamada Y 

PROVIDER: S-EPMC12603838 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature